Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group

被引:24
作者
Zhang, Yingjie [1 ]
Feng, Jinhong [1 ]
Jia, Yuping [1 ]
Xu, Yingying [1 ]
Liu, Chunxi [2 ]
Fang, Hao [1 ]
Xu, Wenfang [1 ]
机构
[1] Shandong Univ, Sch Pharm, Dept Med Chem, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ, Sch Pharm, Dept Pharmaceut, Jinan 250012, Shandong, Peoples R China
基金
国家高技术研究发展计划(863计划);
关键词
1,4-Dithia-7-azaspiro[4,4]nonane-8-carboxylic acid derivatives; Histone deacetylases; Inhibitor; Synthesis; HYDROXAMIC ACID; BIOLOGICAL EVALUATION; HDACS INHIBITORS; PROSTATE-CANCER; GASTRIC-CANCER; IN-VITRO; EXPRESSION; DERIVATIVES; VORINOSTAT; ACETYLASES;
D O I
10.1016/j.ejmech.2011.08.045
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel series of tripeptidomimetics with spiro ring containing sulfur atoms as cap group and linear carbochain as linker was designed and synthesized as HDACs inhibitors. Several compounds possessed more potent HDAC8 inhibitory activity than clinically used drug SAHA, although their HDAC1 inhibitory activities and anti-proliferative activities against human breast cancer cell lines (MCF-7, MDA-MB-231) and prostate cancer cell line (PC-3) were not satisfactory. Among them, compounds 111 and ilk showed excellent potency against HDAC8 (IC50 values were 0.021 +/- 0.004 mu M and 0.035 +/- 0.007 mu M, respectively, whereas SAHA was 0.70 +/- 0.12 mu M), and good selectivity over HDAC1. Up to now, few hydroxamic acid derivatives with linear linker were reported to possess HDAC8 selectivity over HDAC1. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:5387 / 5397
页数:11
相关论文
共 37 条
[1]   Histone Deacetylation An Attractive Target for Cancer Therapy? [J].
Al-Janadi, Anas ;
Chandana, Sreenivasa R. ;
Conley, Barbara A. .
DRUGS IN R&D, 2008, 9 (06) :369-383
[2]   A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas [J].
Balasubramanian, S. ;
Ramos, J. ;
Luo, W. ;
Sirisawad, M. ;
Verner, E. ;
Buggy, J. J. .
LEUKEMIA, 2008, 22 (05) :1026-1034
[3]  
Butler LM, 2000, CANCER RES, V60, P5165
[4]   ROMIDEPSIN FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA [J].
Campas-Moya, Clara .
DRUGS OF TODAY, 2009, 45 (11) :787-795
[5]   Expression profile of histone deacetylase 1 in gastric cancer tissues [J].
Choi, JH ;
Kwon, HJ ;
Yoon, BI ;
Kim, JH ;
Han, SU ;
Joo, HJ ;
Kim, DY .
JAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (12) :1300-1304
[6]   Histone deacetylases (HDACs): characterization of the classical HDAC family [J].
De Ruijter, AJM ;
Van Gennip, AH ;
Caron, HN ;
Kemp, S ;
Van Kuilenburg, ABP .
BIOCHEMICAL JOURNAL, 2003, 370 :737-749
[7]   Histone deacetylase inhibitors: Overview and perspectives [J].
Dokmanovic, Milos ;
Clarke, Cathy ;
Marks, Paul A. .
MOLECULAR CANCER RESEARCH, 2007, 5 (10) :981-989
[8]   On the inhibition of histone deacetylase 8 [J].
Estiu, Guillermina ;
West, Nathan ;
Mazitschek, Ralph ;
Greenberg, Edward ;
Bradner, James E. ;
Wiest, Olaf .
BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (11) :4103-4110
[9]   Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors [J].
Finnin M.S. ;
Donigian J.R. ;
Cohen A. ;
Richon V.M. ;
Rifkind R.A. ;
Marks P.A. ;
Breslow R. ;
Pavletich N.P. .
Nature, 1999, 401 (6749) :188-193
[10]   HDAC inhibitors overcome first hurdle [J].
Garber, Ken .
NATURE BIOTECHNOLOGY, 2007, 25 (01) :17-19